Radiation plus chemotherapy as adjuvant therapy for rectal cancer Journal Article


Author: Minsky, B. D.
Article Title: Radiation plus chemotherapy as adjuvant therapy for rectal cancer
Abstract: The most common neo-adjuvant therapy for rectal cancer is chemotherapy and concurrent radiation therapy. In general, it is delivered pre-operatively for patients with clinical evidence of T3-4 disease or post-operatively in patients who have undergone surgery and have T3 and/or N1-2 disease. This chapter reviews the rationale and results for neo-adjuvant therapy, the selection process for pre-operative versus post-operative treatment, and new approaches and controversies.
Keywords: survival; cancer chemotherapy; cancer survival; treatment outcome; survival analysis; cancer surgery; survival rate; clinical trial; review; cancer recurrence; postoperative period; fluorouracil; diarrhea; drug efficacy; multimodality cancer therapy; patient selection; side effect; capecitabine; adjuvant therapy; cancer adjuvant therapy; cancer patient; cancer radiotherapy; postoperative care; preoperative care; radiation dose; chemotherapy, adjuvant; combined modality therapy; neoadjuvant therapy; radiotherapy, adjuvant; cancer staging; antineoplastic agent; evidence based medicine; evidence-based medicine; blood toxicity; antineoplastic combined chemotherapy protocols; risk factors; risk factor; cancer mortality; irinotecan; drug fatality; preoperative period; folinic acid; adjuvant chemotherapy; oxaliplatin; rectal neoplasms; rectum cancer; rectum tumor; hematologic disease; rectum surgery; rectum resection; rectal cancer; anus sphincter; raltitrexed; levamisole; uft; humans; prognosis; human
Journal Title: Best Practice & Research: Clinical Gastroenterology
Volume: 16
Issue: 2
ISSN: 1521-6918
Publisher: Elsevier Ltd  
Date Published: 2002-04-01
Start Page: 267
End Page: 282
Language: English
DOI: 10.1053/bega.2002.0285
PUBMED: 11969238
PROVIDER: scopus
DOI/URL:
Notes: Export Date: 14 November 2014 -- Source: Scopus
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Bruce Minsky
    306 Minsky